{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-303934","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2022-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.895178+00:00","generated_at":"2026-06-21T04:43:46.321123+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Karyopharm reports Phase 1 selinexor+ruxolitinib data: 92% spleen response at week 24 in myelofibrosis","bullets":["At week 24, 92% (11/12) evaluable patients achieved ≥35% spleen volume reduction (SVR35).","Median spleen volume reduction of 45% at week 12 and 49% at week 24.","67% (4/6) evaluable patients achieved ≥50% symptom reduction (TSS50) at week 24.","57% (13/23) transfusion-independent patients maintained or improved hemoglobin levels.","Common grade 3-4 AEs: anemia (37%) and thrombocytopenia (21%), both reversible."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-303934","json":"https://secwatch.observer/filing/0001193125-22-303934.json","markdown":"https://secwatch.observer/filing/0001193125-22-303934.md","text":"https://secwatch.observer/filing/0001193125-22-303934.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522303934/0001193125-22-303934-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522303934/d426577d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T04:43:46.321123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}